Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 2.240
+0.150 (7.18%)
At close: Mar 27, 2026
Sprint Bioscience AB Market Cap
Sprint Bioscience AB has a market cap or net worth of 236.35 million as of March 27, 2026. Its market cap has increased by 150.76% in one year.
Market Cap
236.35M
Enterprise Value
109.65M
Revenue
167.17M
Ranking
n/a
PE Ratio
2.29
Stock Price
2.24
Market Cap Chart
Since November 7, 2014, Sprint Bioscience AB's market cap has increased from 62.49M to 236.35M, an increase of 278.20%. That is a compound annual growth rate of 12.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 236.35M | 52.38% |
| Dec 30, 2025 | 155.11M | 40.43% |
| Dec 30, 2024 | 110.46M | -8.82% |
| Dec 29, 2023 | 121.14M | 449.78% |
| Dec 30, 2022 | 22.03M | -88.47% |
| Dec 30, 2021 | 191.05M | 17.26% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Oncopeptides AB | 377.43M |
| Bio-Works Technologies AB | 376.82M |
| Ascelia Pharma AB | 366.02M |
| Intervacc AB | 306.39M |
| Mendus AB | 301.84M |
| Elicera Therapeutics AB | 270.83M |
| Xintela AB | 206.70M |
| Initiator Pharma | 205.36M |